Siavelis et al.13combined multiple drug repurposing tools to prioritise anti-AD candidates, while Taubes et al.14established apolipoprotein E (APOE) genotype-dependent transcriptomic signatures for screening APOE-related AD drugs. This evidence concerns the gene APOE and Alzheimer disease.